Oct. 6, 2020βBeckman Coulter has received emergency use authorization for its Access Interleukin-6 assay from the FDA. Access IL-6 is a fully automated immunoassay designed to detect IL-6 levels in serum and plasma. The results can be used to help physicians identify a severe inflammatory response and determine the risk of intubation with mechanical ventilation in patients with COVID-19.
βAn assay that helps identify patients at risk for respiratory failure and intubation in the care pathway has the potential to significantly improve COVID-19 patient care and outcomes,β Shamiram R. Feinglass, MD, MPH, chief medical officer, Beckman Coulter, said in a press statement.